Clinical trials: Abiraterone ACetate
Prostate Cancer
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine…
- Trial name
- NCT06689163
- Testing
- HRS-1167 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery.
- Trial name
- NCT01946165
- Testing
- Abiraterone Acetate, Prednisone, Enzalutamide
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Diagnosed With Metastatic Prostate Cancer
Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer
Objectives of Study： Primary Objective: To observe and evaluate the safety of abiraterone acetate tablets (II) and conventional abiraterone tablets in patients with metastatic prostate cancer under real-world conditions…
- Trial name
- prostate (NCT07721532)
- Testing
- abiraterone acetate tablets (II)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostatic Neoplasms
A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants
The purpose of this observational study of metastatic castration-resistant prostate cancer (mCRPC) participants is to explore whether or not there are differences between participants treated with abiraterone acetate and…
- Trial name
- AQUARiUS (NCT02813408)
- Where
- 26 sites in Denmark, France and 1 more
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Prostate Cancer
Abiraterone-Rechallenge Study for CRPC Patients
To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.
- Trial name
- ABI-RE (NCT02656615)
- Testing
- abiraterone acetate
- Where
- 3 sites in Switzerland
- Volunteers
- 4 people
- Sponsor
- Aurelius Omlin
Prostate Cancer
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Radium-223 is indicated for the treatment of patients with mCRPC with symptomatic bone metastases and no known visceral metastatic disease.
- Trial name
- EXCAAPE (NCT03002220)
- Testing
- radium-223
- Where
- 6 sites in Spain
- Volunteers
- 52 people
- Sponsor
- MedSIR
Healthy Volunteers
A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants
The purpose of this study is to evaluate the relative bioavailability of 4 new formulations of abiraterone acetate compared to the current commercial formulation.
- Trial name
- NCT01897389
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey